Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases

Review of clinical features and antibody specificities

Toshio Ariga, Robert K Yu

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that usually develops following a respiratory or intestinal infection. Although the pathogenic mechanisms of GBS have not been fully established, both humoral and cell-mediated immune factors have been shown to contribute to the disease process. Several antiglycosphingolipid (anti-GSL) antibodies have been found in the sera of patients with GBS or related diseases. Measurements of these antibody titers are very important in the diagnosis of GBS and in evaluating the effectiveness of treatments in clinical trials. The most common treatment strategies for these disorders involve plasmapheresis and the use of steroids for reducing anti-GSL antibody titers to ameliorate patients' clinical symptoms. Administration of intravenous immunoglobulin may also be beneficial in the treatment of neuropathies by suppressing the immune-mediated processes that are directed against antigenic targets in myelin and axons. In certain demyelinating neuropathies, the destruction or malfunctioning of the blood-nerve barrier, which results in the leakage of circulating antibodies into the peripheral nerve parenchyma, has been considered to be an initial step in development of the disease process. In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located. These malfunctions thus contribute to the pathogenic mechanisms of certain demyelinating neuropathies.

Original languageEnglish (US)
Pages (from-to)1-17
Number of pages17
JournalJournal of Neuroscience Research
Volume80
Issue number1
DOIs
StatePublished - Apr 1 2005

Fingerprint

Antibody Specificity
Antibodies
Blood-Nerve Barrier
Ranvier's Nodes
Glycoconjugates
Guillain-Barre Syndrome
Plasmapheresis
Intravenous Immunoglobulins
Immunologic Factors
Myelin Sheath
Ion Channels
Peripheral Nerves
Axons
Epitopes
Steroids
Carbohydrates
Clinical Trials
Wounds and Injuries
Therapeutics
Infection

Keywords

  • Antiglycolipid antibodies
  • Glycosphingolipids
  • Guillain-Barré syndrome

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases : Review of clinical features and antibody specificities. / Ariga, Toshio; Yu, Robert K.

In: Journal of Neuroscience Research, Vol. 80, No. 1, 01.04.2005, p. 1-17.

Research output: Contribution to journalReview article

@article{c73b84114e12464dbfd936c1716e6594,
title = "Antiglycolipid antibodies in Guillain-Barr{\'e} syndrome and related diseases: Review of clinical features and antibody specificities",
abstract = "Guillain-Barr{\'e} syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that usually develops following a respiratory or intestinal infection. Although the pathogenic mechanisms of GBS have not been fully established, both humoral and cell-mediated immune factors have been shown to contribute to the disease process. Several antiglycosphingolipid (anti-GSL) antibodies have been found in the sera of patients with GBS or related diseases. Measurements of these antibody titers are very important in the diagnosis of GBS and in evaluating the effectiveness of treatments in clinical trials. The most common treatment strategies for these disorders involve plasmapheresis and the use of steroids for reducing anti-GSL antibody titers to ameliorate patients' clinical symptoms. Administration of intravenous immunoglobulin may also be beneficial in the treatment of neuropathies by suppressing the immune-mediated processes that are directed against antigenic targets in myelin and axons. In certain demyelinating neuropathies, the destruction or malfunctioning of the blood-nerve barrier, which results in the leakage of circulating antibodies into the peripheral nerve parenchyma, has been considered to be an initial step in development of the disease process. In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located. These malfunctions thus contribute to the pathogenic mechanisms of certain demyelinating neuropathies.",
keywords = "Antiglycolipid antibodies, Glycosphingolipids, Guillain-Barr{\'e} syndrome",
author = "Toshio Ariga and Yu, {Robert K}",
year = "2005",
month = "4",
day = "1",
doi = "10.1002/jnr.20395",
language = "English (US)",
volume = "80",
pages = "1--17",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases

T2 - Review of clinical features and antibody specificities

AU - Ariga, Toshio

AU - Yu, Robert K

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that usually develops following a respiratory or intestinal infection. Although the pathogenic mechanisms of GBS have not been fully established, both humoral and cell-mediated immune factors have been shown to contribute to the disease process. Several antiglycosphingolipid (anti-GSL) antibodies have been found in the sera of patients with GBS or related diseases. Measurements of these antibody titers are very important in the diagnosis of GBS and in evaluating the effectiveness of treatments in clinical trials. The most common treatment strategies for these disorders involve plasmapheresis and the use of steroids for reducing anti-GSL antibody titers to ameliorate patients' clinical symptoms. Administration of intravenous immunoglobulin may also be beneficial in the treatment of neuropathies by suppressing the immune-mediated processes that are directed against antigenic targets in myelin and axons. In certain demyelinating neuropathies, the destruction or malfunctioning of the blood-nerve barrier, which results in the leakage of circulating antibodies into the peripheral nerve parenchyma, has been considered to be an initial step in development of the disease process. In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located. These malfunctions thus contribute to the pathogenic mechanisms of certain demyelinating neuropathies.

AB - Guillain-Barré syndrome (GBS) is an acute inflammatory polyradiculoneuropathy that usually develops following a respiratory or intestinal infection. Although the pathogenic mechanisms of GBS have not been fully established, both humoral and cell-mediated immune factors have been shown to contribute to the disease process. Several antiglycosphingolipid (anti-GSL) antibodies have been found in the sera of patients with GBS or related diseases. Measurements of these antibody titers are very important in the diagnosis of GBS and in evaluating the effectiveness of treatments in clinical trials. The most common treatment strategies for these disorders involve plasmapheresis and the use of steroids for reducing anti-GSL antibody titers to ameliorate patients' clinical symptoms. Administration of intravenous immunoglobulin may also be beneficial in the treatment of neuropathies by suppressing the immune-mediated processes that are directed against antigenic targets in myelin and axons. In certain demyelinating neuropathies, the destruction or malfunctioning of the blood-nerve barrier, which results in the leakage of circulating antibodies into the peripheral nerve parenchyma, has been considered to be an initial step in development of the disease process. In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located. These malfunctions thus contribute to the pathogenic mechanisms of certain demyelinating neuropathies.

KW - Antiglycolipid antibodies

KW - Glycosphingolipids

KW - Guillain-Barré syndrome

UR - http://www.scopus.com/inward/record.url?scp=17744396351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744396351&partnerID=8YFLogxK

U2 - 10.1002/jnr.20395

DO - 10.1002/jnr.20395

M3 - Review article

VL - 80

SP - 1

EP - 17

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 1

ER -